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Abstract
Objective: Recruiting into clinical trials on time and on target is a major challenge and yet often goes unreported. This study evaluated the
adjustment to procedures, recruitment and screening methods in two multi-centre pharmaceutical randomised controlled trials (RCTs) for
hearing-related problems in adults. Design: Recruitment monitoring and subsequent adjustment of various study procedures (e.g. eligibility
criteria, increasing recruiting sites and recruitment methods) are reported. Participants were recruited through eight overarching methods:
trial registration, posters/flyers, print publications, Internet, social media, radio, databases and referrals. The efficiency of the recruitment
was measured by determining the number of people: (1) eligible for screening as a percentage of those who underwent telephone prescreening and (2) randomised as a percentage of those screened. Study sample: A total of 584 participants completed the pre-screening
steps, 491 screened and 169 participants were randomised. Results: Both RCTs completed adjustments to the participant eligibility, added
new study sites and additional recruitment methods. No single recruitment method was efficient enough to serve as the only route to
enrolment. Conclusion: A diverse portfolio of methods, continuous monitoring, mitigation strategy and adequate resourcing were essential
for achieving our recruitment goals.

Key Words: Pharmacology, aging, speech perception, tinnitus
Introduction
As new pharmaceutical treatments are being developed for hearingrelated disorders in the adult population (e.g. age-related hearing
loss [ARHL], tinnitus), hearing healthcare professionals may be
asked to participate in the recruitment of participants into a clinical
trial. Participant recruitment is an essential component of conducting a successful clinical trial, yet it is one of the most difficult and
least predictable elements. Investigators often overestimate the
number of available potential participants who meet the inclusion
criteria (Thoma et al. 2010) and many of those whom meet
eligibility fail to be recruited (Allen et al. 1998). No matter what the
clinical specialty, many trials fall short of their recruitment targets
(see McDonald et al. 2006; Strasser, Cola, and Rosenblum 2013;
Bower et al. 2014) and insufficient or untimely recruitment into
randomised controlled trials (RCTs) has serious consequences.

When the planned sample size is not achieved, the risk of making
the erroneous conclusion that a drug is not effective is increased and
external validity is diminished. When initial recruitment strategies
are not successful, the trial period may need to be extended or the
number of recruiting sites increased, all of which increases
resources and costs. Alternatively, the trial may be abandoned,
results may not be publishable or the findings may have little impact
on patient health and wellbeing.
While we are not aware of any specific publications related to
factors influencing recruitment into hearing-related pharmaceutical
trials, Hong, Fiola, and Feld (2013) found that building relationships
with key stakeholders was an important factor in recruiting
firefighters into an RCT of a hearing protection programme. This
finding is perhaps not surprising as systematic reviews of strategies
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designed to improve recruitment into pharmaceutical trials also
indicate that investigator and participant factors can influence
recruitment rate (Fletcher et al. 2012; Treweek et al. 2013; Huynh
et al. 2014). In general, the results of these systematic reviews
highlight the benefits of making the trial open rather than blinded so
that participants know what treatment they will receive; providing
financial incentives to participants; reducing clinician’s workload;
frequent contact between the trial coordinator and clinicians/trial
site and continuous monitoring. The applicability of these
approaches to increasing recruitment for hearing-related pharmaceutical intervention trials is unknown, particularly as none of the
individual studies included in the systematic reviews related to
hearing disorders.
Although we are not aware of any published reports specific to
recruitment into pharmaceutical trials for hearing-related disorders,
recent trials within hearing healthcare show recruitment challenges.
For example, Piccirillo et al. (2007) conducted an RCT of gabapentin
for tinnitus funded by National Institute of Health in the United States
(US). The recruitment goal was 160 participants (80 gabapentin and
80 placebo), but closed with 135 enrolled (59 gabapentin and 56
placebo). Considerable resources were likely expended on recruitment since 1028 participants were screened. The overall efficiency
was low, with 669 (65%) of those screened not eligible and 224 (22%)
of those eligible declining to participate. A majority of those excluded
(n ¼ 514) had only mild self-reported tinnitus severity. The high
screen-failure rate is not isolated to this tinnitus RCT, as 48% of the
160 adults assessed for eligibility in a trial of an investigational
medicinal product for the prevention of noise-induced hearing loss
also failed to meet eligibility (Kil et al. 2017). In contrast, when
normal hearing participants are being recruited a high efficiency can
be achieved. For example Le Prell et al. (2016) had a relatively low
screen failure rate (26%) in a study focussed on a dietary supplement
to prevent music-induced hearing loss and recruited university
students (aged 18–31 years) who had normal hearing.
While challenges in participant recruitment are widely recognised in many areas of research, recruitment into pharmaceutical
trials for hearing disorders may have some unique challenges. First
is the relative complexity of current approaches to clinical
management of hearing disorders, which can involve general
practitioners (GPs), otologists (ENTs) and audiologists. Second is
the relatively limited experience of the audiologists in participating
in pharmaceutical RCTs. Increased understanding of the efficiency
of methods which can be used to recruit into hearing-related
pharmaceutical trials may therefore be beneficial.
The purpose of this report is to describe the recruitment
monitoring and subsequent adjustment of various study procedures
and describe the recruitment methods for two hearing-related
phase IIa pharmaceutical RCTs: Quest In Eliminating Tinnitus
(QUIET-1) in England and CLARITY-1 in the US. Each RCT
tested the same novel drug compound for associated hearingrelated problems. The sponsor for both trials was the same,
Autifony Therapeutics Ltd, despite the populations recruited being
different across the two RCTs with different regulatory requirements based on country having an influence on methodologies.
Clinical trial support was provided in both trials by the same ISOcertified international Contract Research Organization (CRO),
CROMSOURCE. Hearing expertise support was provided to the
sites by two academic partners: the University of Nottingham for
QUIET-1 and the University South Florida (USF) for the
CLARITY-1. Using data from the academic partners, our aim
was to evaluate the recruitment monitoring and subsequent
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adjustment of various study procedures (e.g. eligibility criteria,
increasing recruiting sites and recruitment methods) and report the
efficiency of recruitment and screening methods to achieve the
planned sample size.

Overview of the RCTs
The QUIET-1 and CLARITY-1 trials had a number of common
elements. Both compared the effect of repeat dosing of AUT00063
relative to a placebo control. AUT00063 is a synthetic molecule
which modulates specific voltage-gated potassium ion channels
present within the neurons of the central auditory system. Both
QUIET-1 and CLARITY-1 were multi-centre, randomised, doubleblind, parallel group, placebo-controlled trials with the primary
endpoint at 28 days after the first drug dosing day. Consented
participants attended between five and six in-clinic visits spread
across a maximum of 10 weeks, with up to two monitoring
telephone calls. Financial compensation was offered to all participants. Once randomised, the drug was taken orally, once daily, for
28 days. Relevant ethical and regulatory agencies approved all
procedures, compensation and recruitment methods.
The two trials were open to recruitment in parallel. QUIET-1
targeted recruitment of up to 152 participants and enrolment was
open from December 2014 until October 2015. CLARITY-1 initially
sought to recruit 100 participants and recruitment was active from
March 2015 until April 2016. For both RCTs, the CRO assigned staff
that served as personal contact points, resolved queries, conducted
monitoring visits and so on. Each site had a designated coordinator
who weekly reported to the CRO the number of people pre-screened,
the number of people attending a screening visit, the number of and
reasons for screen failure and randomisation logs. Weekly recruitment reports for the trial as a whole were created by the CRO and
monitored by the sponsor at a weekly teleconference.
Both RCTs utilised a structured telephone pre-screening interview asking questions about tinnitus/hearing loss, demographic
factors and general physical health status. There was a major
primary difference between the two trials for pre-screening.
Specially, this related to use of a centralised versus decentralised
pre-screening approach. For QUIET-1, the Nottingham site was the
central contact point and two trial administrators conducted
telephone pre-screening interviews. Those who were potentially
eligible were advised to contact their local site to book a screening
visit or ask their GP to write a letter. For CLARITY-1, prescreening was decentralised, with each site independently responsible for telephone interviews.
Once the potential participants passed the telephone prescreening they moved to on-site eligibility screening after completing the informed consent process. Measures to ensure general good
health included physical examination, vital signs, urinalysis,
haematology and biochemistry, medical history, electrocardiography and medication review. A number of eligibility criteria were
common to both RCTs and these are presented in Supplementary
File A. The RCT designs had a number of additional differences
relating to eligibility criteria, number and type of recruiting sites
and planned recruitment methods, as described below.

Participant eligibility
For QUIET-1, the therapeutic target was subjective tinnitus
associated with ARHL and for CLARITY-1 it was difficulty
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Table 1. Eligibility criteria that were specific to QUIET-1, including a history of approved substantial changes to the Clinical Trial
Protocol.
QUIET-1 specific inclusion criteria (version 1.5, 9 July 2015)

History of substantial changes to the protocol

Females of child-bearing potential must have a negative pregnancy test at screening and
baseline visits and practice two reliable methods of contraception throughout the study.
Pure Tone Average (for frequencies at 0.5, 1, 2 and 4 kHz)  60 dB hearing level (HL), across
the two ears.

Sensorineural hearing loss defined by any single audiometric threshold estimate 420 dB for
frequencies at 0.5, 1, 2, 4, 6 and 8 kHz.
Duration of tinnitus 6 and 18 months at enrolment.
English speaking male or female.
18 y of age.
UK residents, registered with a UK General Practitioner.
Stable tinnitus (consistent from day to day).
Score 24 and 68 on the Tinnitus Functional Index (TFI; Meikle et al. 2012).
If a hearing aid or sound generator user then confirmed consistent daily device usage over the
past six months.

V1.1 (14 Aug 2014) amended to ensure that women use
two methods of contraception.
V1.3 (13 Nov 2014) amended to include 20 and 60 dB HL
in the Pure Tone Average calculation.V1.4 (9 Feb
2015) requirement for Pure Tone Average 20 dB
removed.
V1.4 (9 Feb 2015) individual frequency thresholds
420 dB instead of lower Pure Tone Average 20 dB.

QUIET-1 specific exclusion criteria (version 1.5, 2 July 2015).

History of substantial changes to the protocol.

Surgical or medical condition that would be expected to significantly affect absorption of
medicines.

V1.3 (9 Nov 2014) amended to include only those
surgeries or medical conditions expected to affect
absorption.

Any acute disabling tinnitus.
Central nervous system pathologies (such as multiple sclerosis, Parkinson’s disease etc.).
Moderate or severe depression or generalised anxiety as indicated by a score of 11 out of 21
on the Hospital Anxiety and Depression Scale (Zigmond and Snaith 1983).
Use of central nervous system active drugs except analgesics and those specified in the
Clinical Trial Protocol.
Presence or history of relevant severe adverse reaction to any drug or a history of sensitivity
to potassium channel modulators.
Tinnitus as a concomitant symptoms of a known otological condition (including but not
limited to otitis externa, otitis media, otosclerosis, cholesteatoma, Ménière’s disease or
other vestibular problems, acoustic neuroma or temporo-mandibular joint disorder).
Intermittent tinnitus (comes and goes from one day to the next).
Pulsatile tinnitus (rhythmical sounds that often beat in time with the heartbeat).
Severe hearing impairment such that verbal communication is unreliable.
Participation in a hearing study, involving an intervention, within three months from the last
study visit.

understanding speech in noise associated with ARHL. For this
reason, there were differences across the trials in terms of eligibility
criteria. Table 1 provides details specific to the QUIET-1 trial,
according to the final version of the Clinical Trial Protocol (version
1.5), while Table 2 provides details specific to CLARITY-1
according to the final protocol version (version 4.0). For QUIET-1,
audiometric testing ensured sensorineural hearing loss and the score
on the Tinnitus Functional Index (TFI; Meikle et al. 2012) identified
those with moderate to severe tinnitus symptoms (Table 1). For
CLARITY-1 (Table 2), audiometric testing ensured a strict hearing
loss configuration and a significant difficulty with understanding
speech in noise measured by the Quick Speech-in-Noise Test
(QuickSIN; Killion et al. 2004). Further screening tests excluded
individuals with any other relevant impairments (e.g. cognitive
impairment).

Recruiting sites
It was anticipated that 10 National Health Service (NHS) hospital
sites would be sufficient to recruit the 152 target for QUIET-1.
Two ‘‘backup’’ sites were identified as a mitigation for slow

recruitment. Similarly, it was anticipated that 10 sites would be
sufficient to reach the 100 target for CLARITY-1. All US sites were
established ENT or Audiology practices or a research institute with
a collaborating ENT/Audiology partner.

Recruitment methods
Across both trials there were eight recruitment methods. The
methods utilised were primarily the result of the academic
partner’s experiences with recruitment into non-pharmaceutical
intervention studies for adults with ARHL and/or tinnitus in the
two countries. Over the course of both trials, a small number of
diverse methods to raise awareness of the study evolved. Both the
initial planned methods and those that evolved over time are
described below.
(1) Trial registration: In an effort to increase transparency to all
individuals potentially interested in participation in clinical
research, trial registration is required. QUIET-1 and
CLARITY-1
were
registered
on
ClinicalTrials.gov

Recruiting into ENT and Audiology Clinical Trials
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Table 2. Eligibility criteria that were specific to CLARITY-1, including a history of approved substantial changes to the Clinical Trial
Protocol.
CLARITY-1 specific inclusion criteria (version 4.3, 24 February 2016)

History of substantial changes to the protocol

Males who are sexually active must use a barrier method, unless vasectomised.
Females must be confirmed to be of non-childbearing potential.
Speech-in-noise deficit as shown to be equal or greater than 5 dB signal-to-noise ratio (SNR)
on the QuickSIN test presented binaurally.
Audiology criteria: a) air conduction thresholds at 2 kHz 60 dB HL, b) pure tone audiometry
at 0.5, 1 and 2 kHz cannot exceed 45 dB HL, c) no air conduction threshold 475 dB HL at
4 kHz in both ears, d) no greater than a 15 dB HL difference between ears and e) no recent
history of middle ear disease.
Willing to refrain from significant non-study medication following the baseline visit.
Mother-tongue American English, male or female.
50–89 years of age.

Version 3.0 (22 Oct 2015) amended to relax configuration criteria removing restriction on air conduction
at 0.25, 0.5 and 1 KHz 40 dB HL in both ears and
removed restriction of air conduction threshold being
less than 75 dB HL at 3 and 6 Hz.

Version 3.0 (22 Oct 2015) amended to relax age criteria
from 60–89 years to 50–89 years of age.

Reporting difficulty in hearing speech in noisy environments.
CLARITY-1 specific exclusion criteria (version 4.3, 24 February 2016)

History of substantial changes to the protocol

History of sudden onset hearing loss.
Present conductive hearing loss of greater than 15 dB difference between air- and boneconduction audiometry at two or more consecutive frequencies.
Montreal Cognitive Assessment 522.
Current hearing aid user or previous user of hearing aids 6 months ago (intermittent user)
and 3 years (consistent user).
Score 430 on the TFI (Meikle et al. 2012).

Version 3.0 (22 Oct 2015) amended to relax tinnitus
criteria from TFI greater than 24 to 30.

History of ototoxic medication such as cisplatin or history of dynamic cochlear pathology or
chronic middle ear disease.
Currently taking or planning to take medications that are prohibited by the Clinical Trial
Protocol.
Professional musician with around five years or more musical training and performance.
Any acute disabling illness.

(NCT02315508 and NCT02345031, respectively). Information
about CLARITY-1 was also registered on a second trial
website (www.centerwatch.com).
(2) Posters/flyers: Both trials included the development and
distribution of posters and flyers for display and dissemination.
The four designs approved for QUIET-1 are shown in
Supplementary File B and the three designs for CLARITY-1
in Supplementary File C. For QUIET-1, 12,800 posters were
printed using all four designs and 3824 (31.6%) were
distributed to GP centres, pharmacies and local hospitals by
all trial sites. One of the sites requested electronic pdfs for
display screens in waiting rooms. Electronic versions of the
CLARITY-1 materials were made available to all study sites
for local customisation. At USF, the posters were placed in
multiple locations across the campus and electronic versions
were posted on display screens in waiting rooms of the medical
clinics.
(3) Print publications: QUIET-1 budgeted for one planned paid
feature article in a regional community magazine which
targeted the post-60 year-old age group. In addition, free-ofcharge short editorials appeared in the health section of several
tabloid newspapers reporting on Autifony Therapeutics Ltd or
reporting on tinnitus and QUIET-1. Feature articles were also
published in major hearing-related national magazines in the
United Kingdom, targeting both members of the public and
hearing healthcare professionals (i.e. British Tinnitus
Association, ENT and Audiology News, Hearing Times,

Hearing Link). The Nottingham QUIET-1 site placed paid
short feature articles in six community magazines across the
region, including one which targeted the post-60 year’s age
group, numerous unpaid methods were also introduced around
Nottingham. These included: placing a short feature article in
another community magazine distributing the four different
poster to more diverse locations than initially planned (i.e.
libraries, universities, GP centres and pharmacies across the
surrounding regions) and electronic promotional activities by
the lead academic site. While CLARITY-1 did not initially
budget for any paid print recruitment methods, after nine
months with less than expected participants enrolled in the
study, Autifony Therapeutics Ltd placed a paid featured
advertisement in ‘‘Audiology Today’’ (http://www.audiology.org/) with 12,000 professional members. In addition,
two paid advertisements were placed in local newspapers
(Tampa Bay Times and The Florida Healthcare News), with
circulations of 35,000 and 20,000, respectively.
(4) Internet: Autifony Therapeutics Ltd created ‘‘clinical trial’’
webpages (no longer active) on their website which directed
viewers to contacts for each trial. QUIET-1 feature articles and
updates were published on the webpages of Action on Hearing
Loss, British Tinnitus Association and the lead academic site.
CLARITY-1 feature articles and updates were published on
USF’s webpages and press releases were submitted to several
online science and technology forums that provided readers
with general information about the trial.
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(5) Social media: QUIET-1 utilised social media platforms, but
creating abbreviated recruitment announcements were posted
into Facebook and Twitter by the local hospital (@nuhresearch
1200 followers) and lead academic site (@hearingnihr 600
followers). These announcements were forwarded to additional
pages. Although not a part of the original recruitment plan, the
USF site engaged in a social media campaign which focussed
on posting and sharing posts on various university-affiliated
Facebook accounts.
(6) Referral: Referrals from a hearing healthcare professional
primarily came from each principal investigator or from other
ENTs and audiologists. E-mail dissemination, presentations at
clinician meetings and word-of-mouth raised awareness and
encouraged hearing health professionals to inform potential
participants of the trial. Only done in CLARITY-1, other
healthcare providers serving potential participants in the local
area were sent a ‘‘Dear Doctor Letter’’ informing them about
CLARITY-1. These routes were initially planned personal
referrals in hopes of spreading the word about the study and
encouraging individuals that knew about the study to share
with others as a form of personal referrals. Besides patient
referrals from healthcare professionals, both sites utilised
methods to increase personal referrals. In the Nottinghamshire
area, updates appeared in the quarterly newsletter for the lead
academic site which had a distribution of over 1000 readers via
post and email. For QUIET-1 ad hoc unplanned other personal
referrals came from more informal channels, namely relevant
charitable organisations with telephone helplines, Tinnitus
Support Groups (including presentations to these groups),
online discussion forums and personal recommendation by
word-of-mouth. Similarly for CLARITY-1, USF has an ‘‘optin’’ listserv for current and previous faculty, staff, and students
who are willing to receive a variety of announcements
including current study alerts. A study-alert message was
sent to all employees on the USF listserv. In a similar fashion,
USF also maintains alumni e-mail distribution lists and an
announcement was sent to these lists informing subscribers
about the CLARITY-1 study.
(7) Radio: Numerous local BBC and commercial radio stations
were used to broadcast short unpaid interviews with local trial
site staff about tinnitus and the launch of QUIET-1. This
method of recruitment was not utilised for CLARITY-1.
(8) Database review: For CLARITY-1 the primary planned
recruitment method was through database review, either an
electronic medical record or other custom local database, for
identification of potential participants. While the National
Health Services in the UK does have electronic medical
records, information about tinnitus is not systematically
captured, so database review was not a viable method for the
identification of potential participants for QUIET-1 trial.

Recruitment monitoring
Recruitment tactics and other feedback to QUIET-1 sites
occurred via email updates, six trial e-newsletters, an investigators kick-off meeting and four teleconferences attended by site
representatives, sponsor and CRO. Feedback to CLARITY-1 sites
with an initial investigators kick-off meeting then summary
updates occurred via email updates, eight e-newsletters and two
teleconferences.

Analyses
The data obtained were first examined descriptively in terms of the
ability to meet target goals as a function of protocol modifications
(e.g. participant eligibility criteria and recruiting sites) and then the
recruitment strategies utilised. The efficiency of recruitment method
was calculated, as defined by Lloyd, Dean, and Ada (2010), as a
function of the number of people that completed the telephone prescreening and eligible for screening and also by determining the
number of people randomised as a percentage of those screened.
With respect to pre-screening efficiency calculation, the
Nottingham site conducted centralised pre-screening for QUIET-1
with those passing referred to the closest study site for onsite
screening. For the CLARITY-1 study, pre-screening data were only
available for analysis from the primary academic partner site, USF.
With respect to screening efficiency calculation, full records were
kept at all sites on the number of people attending the screening
visit and the number of screen failures; this allowed for the
calculation of each site’s screening efficiency. The efficiency of the
specific recruitment method leading to randomisation was only
available from Nottingham and USF. Finally, since efficiency
needed to be balanced by a recruitment method’s cost-effectiveness,
relevant data from the two primary academic partners, Nottingham
for QUIET-1 and the USF for CLARITY-1, were examined.

Results
Pre-specified target recruitment numbers were not met in either
trial. For QUIET-1, 91 of the 152 target were consented, screened
and randomised at which point a planned interim analysis was
conducted. As is increasingly occurring in clinical trial practice, one
purpose of the interim analysis was to determine whether or not the
clinical trial, if continued, was likely to achieve its primary efficacy
objective. For the QUIET-1 interim analysis, the futility criteria was
met (p40.39), leading to a recommendation that the study be
discontinued and the sponsor accepted.
Motivated by a slow recruitment rate into CLARITY-1,
reconsideration of the statistical powering for the trial by the
sponsor was conducted. Power was initially determined by a 3 dB
improvement on the QuickSIN test, with an understanding that the
initial target recruitment (n ¼ 100) was greater than indicated
through power analyses (n ¼ 10), it was recommended that the
recruitment goal decrease to 70 instead of 100 and the change was
approved as part of Version 4.0 of the Clinical Trial Protocol on 24
February 2016. At the end of recruitment period (1 April 2016) a
total of 79 individuals were consented, screened and randomised.

Participant eligibility criteria effect on efficiency
Active monitoring across sites occurred for both QUIET-1 and
CLARITY-1. As a result of observing unexpectedly high screen fail
rates, there were substantial amendments to both of the trials
protocols.
Participants in QUIET-1 could fail eligibility on multiple criteria
but the most common reason being failure to meet audiometric
criteria, which accounted for 44 of the 106 exclusions or 41.5%
(Table 1). Although audiometric criterion became a concern early in
the trial based on feedback from site audiologists, only one
participant failed the eligibility screening prior to the first change to
the criterion in protocol amendment in November 2014. Hence,
there was insufficient ‘‘before’’ data to explore the impact of this
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Figure 1. Recruiting sites for QUIET-1 in England (left-hand panel) and for CLARITY-1 in the US (right-hand panel).

particular amendment. As shown in Table 1, a subsequent
amendment in February 2015 relaxed the audiometric criterion
again. Prior to this amendment, five of the nine excluded
participants (55.6%) had failed on hearing status. Following
amendment, this proportion was reduced to 40.6% (39 out of 96).
For CLARITY-1, the leading cause of the 277 screen failures or
68% of total failures, was the absence of a significant speech-innoise deficit as measured by the QuickSIN (see Table 2). The
QuickSIN requirement could not be adjusted as the participants
needed to demonstrate a deficit in speech-in-noise recognition and
reducing the entry criteria would include clinically normal
performance with no room for improvement. However, relaxing
the audiometric criteria defining ARHL did improve recruitment
(Table 2).

Recruiting sites
For both RCTs, more than the 10 planned sites were opened to
support the slower than expected recruitment and mitigate for the
delay in opening certain sites. Figure 1 illustrates the location of all
sites that screened participants.
Tables 3 and 4 report the site timelines, screening and
randomisation activity at each site. For QUIET-1, an additional
eight sites including the two original backups were opened, while
for CLARITY-1, three sites were added. Quick identification and
qualification of new sites, as well as a focus on those familiar with
delivering clinical trials were beneficial.

Efficiency of recruitment
Table 5 displays the data from the sites of the academic partners for
the different recruitment methods at the pre-screening and then
screening stage for academic sites for the QUIET-1 and CLARITY1 trials, respectively. In the table, the specific recruitment methods
are listed under larger categories and these larger categories were
essentially used in both RCTs with the exception of ‘‘Radio’’ being
solely used in QUIET-1 and ‘‘Database review’’ being a planned
recruitment method for CLARITY-1. All recruitment methods are
noted as either being planned/unplanned and paid/unpaid. Both
RCTs added additional recruitment methods (unplanned) to increase
recruitment along the course of the trials. While ‘‘Posters/flyers’’

Table 3. Timeline for opening sites to QUIET-1 recruitment, with
screening and randomisation listings.
Site
numbera
03
09
08
02
04
10
06
13
12
01d
17
18
14
15
19

Date opened
for recruiting
10 October 2014
10 October 2014
17 October 2014
23 October 2014
27 October 2014
3 November 2014
6 November 2014
21 January 2015
11 February 2015
17 February 2015
23 April 2015
14 May 2015
22 June 2015
22 June 2015
28 July 2015

Participants
Participants
screened
randomised to
Efficiencyc
b
(n ¼ 214) treatment (n ¼ 91)
(%)
22
12
14
32
29
13
4
9
7
28
6
14
2
10
12

11
6
8
14
15
6
1
4
2
7
3
6
0
4
4

50
50
57
44
52
46
25
44
29
25
50
43
0
40
33

a

Three sites were opened, but not listed because they did not screen
any participants before the trial was terminated.
b
It should be noted that a ‘‘per protocol’’ population is not available
and that a proportion of those randomised were not per protocol.
c
Efficiency of recruitment at each site refers to the number of
participants randomised as a percentage of those screened.
d
The Academic Partner was at site 01.
generated the most pre-screens for QUIET-1 (n ¼ 102), this was a
smaller recruitment mode for CLARITY-1 (n ¼ 14). Also interesting, the Internet was a much more popular route for Nottingham
(n ¼ 76) than at USF (n ¼ 2). These data were used to determine the
efficiency of the recruitment methods in terms of (1) pre-screening
and (2) screening as discussed below.

ELIGIBILITY

AS A PERCENTAGE OF THOSE WHO UNDERWENT

TELEPHONE PRE-SCREENING: PRE-SCREENING EFFICIENCY

The numbers of telephone pre-screening calls completed and the
individuals who passed the pre-screening are reported in Table 5
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Table 4. Timeline for opening sites to CLARITY-1 recruitment,
with screening and randomisation listings.

Site
number
01c
04
12
13
14
15
18
05
08
11
17
02
19

Date opened
to recruiting

Participants
screened
(n ¼ 277)

Participants
randomised
to treatment
(n ¼ 78)a

Efficiencyb
(%)

5 March 2015
5 March 2015
18 May 2015
26 May 2015
26 May 2015
9 June 2015
13 July 2015
15 August 2015
11 September 2015
9 September 2015
9 September 2015
2 October 2015
12 October 2015

45
38
10
19
16
22
21
8
1
32
30
6
29

11
23
3
7
2
2
2
4
0
4
8
1
12

24
64d
30
37
13
9
10
50
0
13
23
0
4

a

It should be noted that a ‘‘per protocol’’ population is not available
and that a proportion of those randomised were not per protocol.
b
Efficiency of recruitment at each site refers to the number of
participants randomised as a percentage of those screened.
c
The Academic Partner was at site 01.
d
Denotes an inflated efficiency since the site randomised 11
participants not according to protocol who may not have met the
eligibility criteria.

and this information was also used to determine the pre-screening
efficiency of the different recruitment methods (top panel, Figure
2). A higher pre-screening efficiency indicates that people responding to a particular method were more likely to pass pre-screening
and invited to attend an in-person screening visit.
Nottingham was the pre-screening coordinating site for all
QUIET-1 sites. The Nottingham staff conducted 425 structured prescreening interviews between 2 December 2014 and 8 October
2015. Of these, 181 failed on a specific criterion for tinnitus
(duration 6 and 18 months at enrolment), with the majority
(n ¼ 179) experiencing chronic tinnitus symptoms. A further 29
participants were excluded because they were taking concomitant
medications that were not permitted in the Clinical Trial Protocol.
As can be seen in Figure 2, although the absolute number of planned
referrals from a healthcare professional in QUIET-1 was small, the
efficiency of this route at pre-screening was the highest (58%),
certainly relative to the more costly printed publication methods
(40%) or poster campaigns (37%). Overall and across all recruitment methods, 235 recruits did not pass the pre-screening and were
not eligible for an on-site screening visit, while 190 individuals
were invited to attend a screening visit at the closest QUIET-1 site
(45.7% efficiency).
Unlike QUIET-1 where Nottingham coordinated all pre-screening activity, each CLARITY-1 site conducted their own prescreening. CLARITY-1 pre-screening data were completed at USF
(Table 5, Figure 2). Between 5 March 2015 and 1 April 2016 USF
pre-screened 151 individuals, of whom 106 were excluded as not
eligible, leading to an overall 29.8% pre-screening efficiency.
Reasons for exclusion included: current or recent hearing aid use,
demographics (age, English not the first/primary language and selfreported professional musicians), ineligible hearing loss (not agerelated, caused by ototoxic medications and known asymmetry), use

of prohibited medications, current enrolment in another study and
self-report of severe tinnitus. The CLARITY-1 team anticipated that
the main source of recruitment would be from database review but
while the absolute numbers were high (68 pre-screens), efficiency
was low (16%). Beyond the database recruitment, the planned
methods of trial registration (67%), posters/flyer distribution (36%),
Internet (50%) and referrals (37%) had a combined mean efficiency
rate of 47.5%. The recruitment methods implemented later in the
study (paid newspaper advertisements and social media) had a
combined mean efficiency rate of 45.3%.

ELIGIBILITY

AS A PERCENTAGE OF THOSE WHO UNDERWENT

SCREENING: SCREENING EFFICIENCY

Data was recorded for all of the 214 screening visits conducted
across the 15 QUIET-1 sites (Table 3). Of these, 91 participants
were randomised (42.5% efficiency) and the median efficiency
across sites was 44% (Table 3). Efficiency may be underestimated
since, within the remainder, six individuals had a decision pending
further medical investigation, one person was eligible but declined
to participate and 10 individuals had been screened but were not
taken further due to the study termination. In total, only six of the
123 participants (4.9%) identified as potential participants through
telephone pre-screening strategy were excluded at the screening
visit with the otologist consultant. Six were excluded for tinnitus
duration, with the primary reason being duration. That is, the
potential participants moved out of the eligible time window by the
time of their screening appointment.
Across all 13 CLARITY-1 sites, 277 participants were
screened (Table 4). Of these, 79 participants were randomised
(28.5% efficiency) and the median efficiency across sites was
24% (Table 4). At the USF site, 34 of the 45 participants (76%)
were still excluded at the screening visit and so we concluded
that the pre-screening strategy was only moderately effective. The
moderate efficiency was caused by lack of ability to predict
speech-in-noise performance; thus, results of QuickSIN were a
major stumbling block.
For both RCTs, Table 5 reports the total number of subjects
screened on-site and randomised with respect to recruitment
methods utilised at Nottingham and USF and this information was
also used to determine the screening efficiency of the different
recruitment methods (bottom panel, Figure 2). As the numbers were
small, we do not interpret observed trends. However, worthy of note
is that the ‘‘Internet’’ channels were generally popular routes at the
pre-screening stage, but did not yield any randomised participants at
either site. In addition, both RCTs had acceptable efficiency from
the ‘‘posters/flyers’’ (43% for Nottingham, 60% for USF) although
the pre-screening efficiency was lower for this method (37% for
Nottingham, 36% for USF). Although the absolute number of
healthcare professional was small, these routes were efficient for
both RCTs, certainly relative to the more expensive printed
publications methods.

Resource implications
For QUIET-1, printed media were the most costly method of
recruitment. A recruitment plan was developed at the start of the
trial by a graduate in journalism and marketing at a cost of £3984.
He prepared all of the features that were fed into the newspaper,
poster and magazine advertisements. In addition to this, an estimate
of the total cost for the poster campaigns was £3150, including

0
38
28
10
36
0
25
4
7
46
46
1
1
33
8
25
6
6

30
190

102
75
27
90
7
60
10
13
80
80
4
4
57
11
46
21
21

71
425

Passed
pre-screening

0

Pre-screened

2
8

28

1
1
0
0
0

0
0

0
0

1
2
0
0
1
1

3
2

0

Passed
screening

6

5
3
2
1
1

0
0

5
5

1
4
0
0
2
2

7
6

0

Screened

P,U

P,U
U,U

P,U

P,U

P,P
P,U
P,U
U,P

U,U

P,U

U/Planned,
U/Paid

151

68
68

1
60
8
52

45

11
11

0
23
3
20

1
0

0
1

0
2
2
1

3

3

5

2
2
5

Passed
pre-screening

3

3

14

3
3
14

Pre-screened

45

11
11

0
23
3
20

1
0

0
1

3

3

5

2
2
5

Screened

CLARITY-1b

11

2
2

0
4
1
3

0
0

0
0

0

0

3

2
2
3

Passed
screening

P,U

P,U
P,U

U,U

P,U

U,P

U,P

P,U

P,U

U/Planned,
U/Paid

QUIET-1 data was sourced from the Nottingham site. The number telephone pre-screened was 433, but eight of those were pending a decision at the point of study termination. Hence,
number reported here is n ¼ 425.
b
CLARITY-1 data was sourced from USF. At USF, 151 individuals were pre-screened up to the end of the study.
Each recruitment method is coded as either Unplanned (U) or Planned (P)and Unpaid (U) or Paid (P).

a

Trial registration
Clinicaltrials.gov, centrewatch
Poster/Flyer
Supplementary file B
Supplementary file C
Community posts
Print publication
Regional magazine
Newspaper
Tabloid magazines
Community magazine
National Autifony advert
Internet
Websites, post forums
Websites, press releases
Social media
Facebook and Twitter
Facebook
Referral
Professional
Personal
Radio
Opening announcements
Database review
Clinic/Research database
Unable to code
TOTAL pre-screenings
TOTAL screening visits

Recruitment method

QUIET-1a

Table 5. Efficiency of the different recruitment methods used in the QUIET-1 and CLARITY-1 RCTs.
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Figure 2. Efficiency of the different recruitment methods used in the QUIET-1 and CLARITY-1 RCTs. The top panel shows pre-screening
efficiency measured by determining the number of people eligible for screening as a percentage of those who underwent telephone prescreening. The bottom panel shows screening efficiency measured by the number of randomised participants as a percentage of those
screened.

design, printing, stationery and labour and £1050 for the magazine
campaigns, including publication fees and labour. These figures are
likely to be underestimated because labour costs for dealing with
additional promotional opportunities were not recorded.
Furthermore, labour costs for dealing with telephone and email
queries, separate from the actual telephone pre-screening calls, is
not accounted for.
For CLARITY-1, printed advertisements in local newspapers
were the only recruitment method with a direct site cost ($4364).
Again, this is an underestimate because labour costs of the study
staff who designed the advertisements, obtained regulatory
approval and negotiated the placement in the newspaper were
not available. Although the paid advertisements only yielded three
pre-screening interviews and none continued on to screening, the
potential for good recruitment needs to be acknowledged. The two
local advertisements were placed in March 2016 with recruitment
and enrolment closed on 1 April 2016. The number of calls that
could have potentially lead to successful recruitments were tallied
to 34 individuals from April to June. Thus, the paid advertisements may have been more cost-effective if initiated earlier in the
recruitment phase. Experience suggests that the database review
method was unlikely to be cost-effective. As an example of the
effectiveness of database review, the USF database included 478
adults which was narrowed to 68 who fit the age range, were
known to have ARHL and did not report using hearing aids at
time of last contact. Despite the substantial labour demands
needed to search all database records and complete the 68

identified contacts, only 11 individuals were eligible for screening
and only two were randomised.
The ‘‘posters/flyers’’ used to promote QUIET-1 turned out not
to be so low-cost and low-resource, primarily because of the
substantial labour required to manually enter the local contact
details for each paper copy. The Nottingham site packaged and
posted materials to other sites enabling us to at least track the
demand across sites. For CLARITY-1, sites received electronic
copies of posters/brochures and so greater responsibility for printing
was locally delegated, with less opportunity for tracking posterrelated promotional activities.
Both the telephone pre-screening and screening visits
demanded considerable labour to sustain. For the Nottingham
QUIET-1 team, the resource demand was two-fold. First, the
number and duration of calls was greater than planned. The
protocol planned for a short (15 min) call to assess duration of
tinnitus, relevant medical history and concomitant medications.
However, calls occasionally lasted up to one hour and some
conversations were challenging because the trial staff had to
manage the person’s anticipation to find a cure and disappointment at being excluded. Second, organising the screening visit was
logistically challenging since it required appointments with
multiple professionals who were based across two hospital
campuses. For CLARITY-1, the labour demand was principally
attributable to the high number of screen fails due to the
QuickSIN scores. To conserve resources, study staff were
recommended to start the screening visit with the hearing
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assessment, thus reducing the likelihood of completing unnecessary invasive procedures such as specimen collection for haematology and biochemistry.

Discussion
Multi-site randomised controlled clinical trials are relatively
uncommon in ENT/Audiology clinics, but with high potential for
novel interventions for ARHL and tinnitus there are likely to be
more RCTs in the future. This is the first evaluation of recruitment
methods in hearing-related, multi-site clinical trials in adults. The
present work demonstrates the difficulties that may be encountered
in ENT/Audiology recruitment. Based on our experiences, we have
learned the importance of planning, budgeting, implementing and
monitoring a recruitment plan that is relevant for all sites includes
paid advertisements and has adequate risk mitigation. In this
section, we reflect on the strengths and limitations of our different
recruitment methods so that other study teams may take these into
account when planning future multi-centre pharmaceutical trials in
ENT/Audiology. The primary caveat to our reflections is that the
systematic collection of such data was not planned into the studies.
As a consequence, such information is available in a reliable form
only from the primary academic sites.

Recruitment methods: strengths
Although telephone pre-screening was labour intensive, in general it
contributed positively to the efficiency of the screening visits
because participants with exclusions that were easily identifiable by
verbal questioning could be ruled out. Nevertheless, in both RCTs a
reasonably large proportion failed on audiological criteria that could
only be assessed during an on-site visit. For QUIET-1, this was the
audiometric threshold for identifying a sensorineural hearing loss
and for CLARITY-1, it was performance threshold on the speechin-noise recognition task. The sponsor’s and CRO’s experience in
risk management promoted active monitoring. Regular communication with trial sites helped to identify the need for remedial action
by substantive amendments to the eligibility criteria and by
requesting each site to develop its own ad hoc recruitment plan.
These steps contributed to the ultimate enrolment achievements.
For both RCTs, the internet avenues achieved the greatest
outreach for low cost and low resource, especially given that the
majority were externally maintained. In most cases, trial-specific
details could be found by active searching for hearing-related
research information. Evidence suggests that internet use by older
adults makes this recruitment method worth considering. For
example, about 59% of US adults aged 465 years use the Internet,
with 24% going online multiple times per day (Perrin 2015;
Anderson and Perrin 2016). Based on our QUIET-1 experience, it
appeared that people with chronic tinnitus were likely to use the
Internet to seek out information about clinical trials of tinnitus; in
contrast, experience with CLARITY-1 indicated that people with
ARHL were less likely to do so. We note that another tinnitusrelated clinical study successfully recruited at least 26% of its
participants using Internet recruitment methods (Handscomb et al.
2016), the mode of data collection which was Internet based , could
have enhanced the success rate of this recruitment method (Rosa
et al. 2015). Further research is warranted to determine whether or
not internet recruitments can be successful for studies aimed at
people with ARHL.
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Unpaid newspaper and radio feature sessions were most
effective at specific points in the trial cycle. For the QUIET-1
trial, media channels published and broadcasted promotional stories
(1) when the trial opened for recruitment nationally, (2) when a new
site opened for recruitment locally and (3) if there was specific
newsworthy link to the story. An example of the latter case was a
large-scale campaign planned around the UK Tinnitus Awareness
Week (2–8 February 2015), with the resulting media coverage
having a major (but transient) boost on telephone queries, such that
Nottingham handled 90 telephone pre-screening interviews in
February, compared to 14 in January and 57 in March. Although
efficiency at pre-screening was around 30%, the campaign did have
some drawbacks. There was a strong likelihood of attrition because
many callers lived more than 20 miles travelling distance from a
recruiting site and a large number of calls came from London area,
exceeding the capacity of the London site.

Recruitment methods: limitations
It has been commented that recruitment strategies which work for
some studies often do not work well for others and that it is
important for sites to test out different recruitment methods to find
out what works best (Kye et al. 2009). Nevertheless, our experiences can provide important lessons for ENT/Audiology. Across the
two RCTs, recruitment proved to be more resource intensive and
had a higher proportion of screen failures than initially anticipated
during trial design and planning, requiring an extension to the
recruitment period and the addition of sites. These recruitment
struggles are similar to those reported for other disciplines too
(Lloyd, Dean, and Ada 2010; Usadi et al. 2015).
Similarly a report by Usadi et al. (2015), discussed that
collaborative communication was positive and beneficial in an
evaluation of recruitment strategies for randomised controlled trials
involving infertile couples, both QUIET-1 and CLARITY-1 held
regular teleconferences between recruiting sites and the trial’s data
coordinating centre at which monthly enrolment data and effective
recruitment strategies were shared and good performing sites were
acknowledged. Such techniques seek to achieve ‘‘buy-in’’ from
collaborators by developing a sense of personal ownership and
commitment, techniques perhaps more common to business marketing than to clinical research. While both of the present trials did
maintain contact through newsletters and teleconferences, feedback
from sites suggests that there was room for improvement. For both
trials, sites certainly welcomed the opportunity to discuss recruitment rates, highlight difficulties they were facing and successful
recruitment outlets. However, each recruiting site could not always
be represented at the teleconferences due to conflicting clinical
priorities.
While physician referral can be more effective than advertising
strategies for some intervention trials (Lloyd, Dean, and Ada 2010;
Usadi et al. 2015) professional clinical referral was not as successful
as had been anticipated at either site. Major eligibility criteria were
not routinely assessed in-clinic, so a reasonably large proportion
failed on those criteria at the screening visit. For the same reason, in
CLARITY-1, database review also proved to be a rather inefficient
and a large proportion of those contacted failed at pre-screening
because they used hearing aids (see Table 2). Like others (e.g. Usadi
et al. 2015), professional referrals to CLARITY-1 were found to be
most effective when there was an existing close relationship
between specialties and the trial team. Similarly, Lloyd, Dean, and
Ada (2010) also commented that referral strategies are more
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successful and efficient than advertising strategies at recruiting
community-dwelling stroke survivors. It is likely that referral was
the most successful and efficient when the referring physicians were
able to determine if stroke survivors initially fulfilled the inclusion
criteria prior to contacting the investigators, resulting in higher
efficiency in terms of eligibility as a proportion of those screened.
Of the eight participants coming from professional referral who
were screened by USF, seven came from the wider USF health
network (one ENT and six audiologists) and just one came from
outside the USF practice. This could be because the within-network
referrals came from healthcare providers highly motivated to assist
the primary coordinating site and so they actively looked out for
potentially eligible participants. We also note that neither physician
at the Nottingham or USF sites specialised in areas directly relevant
to the target clinical population (i.e. paediatric and cochlear implant
specialists); thus, the low referral from those physicians is perhaps
not surprising.

Concluding remarks
Taking a business approach to trials has been shown to be beneficial
in several multi-centre trials (McDonald et al. 2011). Adopting an
explicit marketing plan, engaging charities or participants to act as
champions, delivering effective messages to multiple audiences at
multiple levels and achieving clinician and public buy-in are all
known business components (Francis et al. 2007). Additionally,
researchers need to ensure that they have sufficient budget to not
only support staff to recruit participants, but to fund the evaluation
of recruitment strategies in clinical trials. Our management of
QUIET-1 and CLARITY-1 touched upon these factors, but such
business approaches were not consistently planned and resourced at
the outset. Further research is warranted to evaluate the effectiveness of recruitment strategies to ENT/Audiology clinical trials.
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